Welcome to our dedicated page for Solventum SEC filings (Ticker: SOLV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Solventum's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Solventum's regulatory disclosures and financial reporting.
Solventum Corp director Wilson Darryl L. exercised fully vested restricted stock units to receive 3,403 shares of Common Stock on April 30, 2026. The RSUs represented a contingent right to receive one share of common stock per unit upon settlement.
After this non-cash derivative exercise, he directly holds 8,947 shares of Solventum common stock. No open-market purchases or sales were reported in this filing.
Solventum Corp director Karen J. May exercised 3,403 Restricted Stock Units into Common Stock. Each RSU converted into 1 share of Solventum Common Stock at a stated price of $0.00 per unit.
Following the transaction, she directly holds 8,947 shares of Common Stock, and the exercised RSUs are now fully settled. The filing shows an option-style conversion but no open-market sale or purchase of shares.
Solventum Corp director Harris Bernard A Jr exercised previously granted Restricted Stock Units (RSUs) into common stock. He acquired 3,403 shares of Solventum common stock through the conversion of fully vested RSUs, and now directly holds 8,947 common shares in total. No shares were sold in this filing.
Solventum Corp director Glenn A. Eisenberg reported a routine equity compensation event. On April 30, 2026, he exercised fully vested Restricted Stock Units (RSUs) covering 3,403 shares of Common Stock, converting them into directly held shares.
Following this settlement, Eisenberg directly holds 8,947 shares of Solventum Common Stock. The RSUs represented a contingent right to receive one share of Common Stock per unit upon settlement, and all such RSUs referenced in this filing are now fully settled, with no remaining RSU balance shown.
Solventum Corp director Shirley Ann Edwards exercised 3,403 restricted stock units into 3,403 shares of Common Stock. The RSUs were fully vested and converted at a stated price of $0.00 per share. Following the transaction, she directly holds 8,947 shares of Solventum Common Stock. No open-market purchases or sales were reported; this reflects a compensation-related derivative exercise.
Solventum Corp director Susan D. DeVore exercised restricted stock units into common shares. On April 30, 2026, she converted 3,403 RSUs, receiving the same number of Solventum common shares. Following this transaction, she directly holds 8,947 shares of common stock. The RSUs were fully vested and represented a right to receive one share of common stock per unit.
Solventum Corp director Carrie Smith Cox exercised 4,916 restricted stock units into Common Stock. The filing shows these Restricted Stock Units, each representing one share of Common Stock upon settlement, were fully vested and converted at a price of $0.00 per unit.
Following this compensation-related exercise, Cox directly holds 16,400 shares of Solventum Common Stock. The transaction involves a derivative exercise rather than an open-market purchase or sale, so it does not reflect new cash trading activity in the company’s shares.
Solventum Corp director Carlos Alban exercised restricted stock units into common shares. On April 30, 2026, he converted 3,403 Restricted Stock Units, each representing one share of common stock, into 3,403 shares of Solventum common stock in a non-cash transaction at a stated price of $0.00 per unit.
The filing notes these RSUs were fully vested prior to settlement. After the exercise, Alban directly holds 8,947 shares of Solventum common stock. No open-market purchases or sales and no tax-withholding dispositions are reported in this filing, indicating a routine compensation-related equity settlement.
Solventum Corp reports that Vanguard Capital Management beneficially owns 10,875,310 shares of Common Stock, representing 6.27% of the class.
The filing states Vanguard has sole voting power for 1,273,361 shares and sole dispositive power for 10,875,310 shares. The disclosure notes these holdings include securities held for Vanguard funds and managed accounts. The form is signed 04/30/2026.
Solventum Corp’s Chief Accounting Officer, Mary T. Wilcox, exercised previously granted restricted stock units into common shares. On March 27, 2026, she converted 5,199 RSUs, receiving an equal number of common shares. A portion of these shares was then withheld to cover tax obligations.
Of the acquired shares, 1,591 common shares were disposed of through tax withholding at a price of $62.76 per share, leaving Wilcox with 5,256 common shares held directly after the transactions. The RSUs were fully vested at the time of exercise, indicating this was a routine compensation-related event rather than an open-market trade.